Jacob Riis Park, a Manhattan church, the Bum Bum Bar and more. In 360 degrees, visit five sites that helped shape New York City’s L.G.B.T. community and its history.
NYS Entity Status
NYS Filing Date
MAY 22, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2014 - G & O ARCHITECTURE D.P.C.
AROUND THE WEB
- Five Sites of New York’s L.G.B.T. History
Monday Jun 19, 2017
- Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
By LIAM STACK - Monday Jun 19, 2017
The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.
- Gillibrand attacks NY Dem splinter group, which responds in kind
By Will Bredderman - Tuesday Aug 1, 2017
The Democratic splinter group sharing power in the state Senate with Republicans suggested Monday that U.S. Sen. Kirsten Gillibrand do the same in Washington.The political combat began at a...
To view the full story, click the title link.
- In the Huddle With NY Jets Owner Woody Johnson
Friday Oct 15, 2010
Woody Johnson, owner of the New York Jets NFL franchise, joins WSJ's Lee Hawkins for the "WSJ Weekend Conversations" series to talk about the Jets' Super Bowl prospects, co-chairing the 2014 Super Bowl host committee, and his charitable interests.
- Mid-century time capsule in Oakland asks $1.05 million
By Anna Marie Erwert - Tuesday Aug 1, 2017
Designed by acclaimed architect A. Quincy Jones in Oakland’s Sequoyah Hills, 8o1o Shay Dr. is a preserved mid-century and could be yours for $1.05 million. For fans of Eichler-style architecture, Jones is a well-known figure: Beginning in the early 1950s, Jones and his partner Frederick E. Emmons designed and built thousands of “dynamic, livable housing
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]